Profitability
Weight: 20%
F
0
- 5yr Avg ROIC -27.3%
- Operating Margin Trend -14.22 pp/yr
CCCC
C4 Therapeutics, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 19.9 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -43.3%
- 5yr Share-Count CAGR 15.8%
Growth Quality
Weight: 15%
F
23
- 5yr Revenue CAGR -5.9%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -306.8%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 20%
D-
30
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score -1.60
Stability
Weight: 15%
B
70
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 3
- Negative-Revenue Years (5) 2/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 1 added; 1 trimmed.
- Holders
- 2
- Avg Δ position
- +903.5%
- New buys
- 0
- Full exits
- 0